Sanyou Pharmaceuticals and JiAnTeBo Biotechnology Forge Strategic Partnership to Jointly Develop New Agonist Antibody Drugs
SHANGHAI, Aug. 7, 2024 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") and Guangdong JiAnTeBo Biotechnology Co., Ltd. (hereinafter referred to as "JiAnTeBo") have signed a strategic cooperation agreement. Under the leadership of Professor Yin Zhinan, the founder and chairman of JiAnTeBo, the company has made original pioneering discoveries of new targets for metabolic diseases...
Docquity Drives Demand for SIT Pharma’s Duo Probiotics in Thailand, Achieving 31% Sales Growth in 6 months
Docquity's Awareness to Advocacy (A2A) Program and strong local distribution network enabled SIT's duo probiotic sales to surpass the market growth rate of 15% The technology platform boosted SIT's HCP education efforts, more than doubling its reach to 2,000 HCPs within six months and aiming to connect with thousands more over five...
GSK’s Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer
Jemperli in combination with chemotherapy is the first immuno-oncology treatment approved in the frontline setting for this patient population in Singapore. Latest published local registry reported endometrial cancer as the fourth most common cancer and had the ninth highest cancer mortality rate among females in the country. An estimated 20-29% of...
Senhwa Biosciences receives US FDA Study May Proceed letter for the Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory...
TAIPEI and SAN DIEGO, Aug. 7, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced receipt of a "Study May Proceed" letter from the U.S. Food and Drug Administration ("FDA") for the initiation of a Phase...
Datasea’s Digital Technology Subsidiary Selected as Prospective Partner for Future Projects with Subsidiary of China Mobile
The Prospective Partnership with a Subsidiary of China Mobile, one of the World's Largest Mobile Operator, Underscores DTSS' Achievements in 5G-AI Communications BEIJING, Aug. 6, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated in Nevada, engaged in innovative businesses in high-tech intelligent acoustics in the United States, and 5G-Artificial Intelligence...
Lunit’s AI for Tuberculosis Detection Tops in 12-Product Comparative Study
Lancet Digital Health study highlights Lunit INSIGHT CXR as top performer in TB screening, showing promise for improving detection in high-burden settings SEOUL, South Korea, Aug. 6, 2024 /PRNewswire/ -- Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced that its AI-powered chest X-ray analysis software,...
Antimicrobial Materials Sector Surges Amid Hygiene and Health Revolution
Pandemic-Driven Demand Shifts Focus to Safe, Durable, and Natural Compounds SAN ANTONIO, Aug. 6, 2024 /PRNewswire/ -- The antimicrobial materials industry is experiencing unprecedented growth, fuelled by a heightened focus on hygiene and cleanliness post-pandemic. Customers in the plastics, coatings, textiles, fabrics, and ceramics sectors are now prioritising sustainability, hygiene, and health impacts over aesthetics and utility. This shift...
PHYLEX VACCINE ON TRACK TO COMBAT DEADLY NIPAH VIRUS WITH POSITIVE RESULTS OF IMMUNOGENICITY STUDY
DEL MAR, Calif., Aug. 6, 2024 /PRNewswire/ -- Phylex Biosciences has achieved positive results with its new mRNA nanoparticle vaccine against the Nipah virus in an immunogenicity study conducted in collaboration with scientists of the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. The Nipah virus is a pathogen...
Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner
Samsung Biologics to embed PSCI principles into business practices for responsible value chain management Supplier Partnership reaffirms company's commitment to decarbonize and build resilient supply chains INCHEON, South Korea, Aug. 6, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), announced today that the company...
First patient enrollment in the U.S. – A milestone for the global multi-center phase Ⅲ clinical trial of telitacicept for myasthenia gravis
YANTAI, China, Aug. 6, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA:688331), a commercial-stage biotechnology company, announced that the company's self-developed BLyS/APRIL dual targeting fusion protein innovative drug telitacicept has achieved the first patient enrollment in the United States for its global multi-center phase III clinical trial for the...
